Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Viral targets for vaccines against COVID-19
Lianpan Dai, George F. Gao
Nature reviews. Immunology (2020) Vol. 21, Iss. 2, pp. 73-82
Open Access | Times Cited: 1050

Showing 26-50 of 1050 citing articles:

The humoral response and antibodies against SARS-CoV-2 infection
Hai Qi, Bo Liu, Xinquan Wang, et al.
Nature Immunology (2022) Vol. 23, Iss. 7, pp. 1008-1020
Open Access | Times Cited: 144
From delta to Omicron: S1-RBD/S2 mutation/deletion equilibrium in SARS-CoV-2 defined variants
Vasileios Papanikolaou, Aristeidis Chrysovergis, Vasileios Ragos, et al.
Gene (2022) Vol. 814, pp. 146134-146134
Open Access | Times Cited: 137
Structural basis of human ACE2 higher binding affinity to currently circulating Omicron SARS-CoV-2 sub-variants BA.2 and BA.1.1
Linjie Li, Hanyi Liao, Yumin Meng, et al.
Cell (2022) Vol. 185, Iss. 16, pp. 2952-2960.e10
Open Access | Times Cited: 137
Safety of COVID-19 vaccines administered in the EU: Should we be concerned?
Antonio F. Hernández, Daniela Călina, Konstantinos Poulas, et al.
Toxicology Reports (2021) Vol. 8, pp. 871-879
Open Access | Times Cited: 134
WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community
Ivana Knežević, Giada Mattiuzzo, Mark Page, et al.
The Lancet Microbe (2021) Vol. 3, Iss. 3, pp. e235-e240
Open Access | Times Cited: 134
Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines
Weilin Zhou, Wei Wang
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 132
Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?
Theoharis C. Theoharides
Molecular Neurobiology (2022) Vol. 59, Iss. 3, pp. 1850-1861
Open Access | Times Cited: 126
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants
Rüdiger Groß, Michelle Zanoni, Alina Seidel, et al.
EBioMedicine (2021) Vol. 75, pp. 103761-103761
Open Access | Times Cited: 124
Neutralizing Antibody Therapeutics for COVID-19
Aeron C. Hurt, Adam K. Wheatley
Viruses (2021) Vol. 13, Iss. 4, pp. 628-628
Open Access | Times Cited: 118
The emerging SARS-CoV-2 variants of concern
Adekunle Sanyaolu, Chuku Okorie, Aleksandra Marinkovic, et al.
Therapeutic Advances in Infectious Disease (2021) Vol. 8
Open Access | Times Cited: 118
SARS-CoV-2 RBD in vitro evolution follows contagious mutation spread, yet generates an able infection inhibitor
Jiří Zahradník, Shir Marciano, Maya Shemesh, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 116
Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
Kun Xu, Ping Gao, Sheng Liu, et al.
Cell (2022) Vol. 185, Iss. 13, pp. 2265-2278.e14
Open Access | Times Cited: 113
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
Cong Sun, Chu Xie, Guo‐Long Bu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 113
COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations
Qian He, Qunying Mao, Jialu Zhang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 111
A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies
Monika Kumari, Ruei‐Min Lu, Mu‐Chun Li, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 111
Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease
Pan-Pan Zhou, Ge Song, Hejun Liu, et al.
Immunity (2023) Vol. 56, Iss. 3, pp. 669-686.e7
Open Access | Times Cited: 111
Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay
Elena Riester, Peter Findeisen, Johannes Kolja Hegel, et al.
Journal of Virological Methods (2021) Vol. 297, pp. 114271-114271
Open Access | Times Cited: 106
COVID-19 Vaccine Booster: To Boost or Not to Boost
Rahul Shekhar, Ishan Garg, Suman Pal, et al.
Infectious Disease Reports (2021) Vol. 13, Iss. 4, pp. 924-929
Open Access | Times Cited: 103
A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges
Md. Mijanur Rahman, Md. Habib Ullah Masum, Shah Wajed, et al.
VirusDisease (2022) Vol. 33, Iss. 1, pp. 1-22
Open Access | Times Cited: 98
Adaptive Immune Responses and Immunity to SARS-CoV-2
Dragan Primorac, Kristijan Vrdoljak, Petar Brlek, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 88
A tandem-repeat dimeric RBD protein-based covid-19 vaccine zf2001 protects mice and nonhuman primates
Yaling An, Shihua Li, Xiyue Jin, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 1058-1071
Open Access | Times Cited: 81
Association of vitamin D status with COVID-19 and its severity
Jae Hyun Bae, Hun Jee Choe, Michael F. Holick, et al.
Reviews in Endocrine and Metabolic Disorders (2022) Vol. 23, Iss. 3, pp. 579-599
Open Access | Times Cited: 78
Covid-19: evolução temporal e imunização nas três ondas epidemiológicas, Brasil, 2020–2022
Erly Catarina de Moura, Juan José Cortez-Escalante, Fabrício Vieira Cavalcante, et al.
Revista de Saúde Pública (2022) Vol. 56, pp. 105-105
Open Access | Times Cited: 78
Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2
Chiara Pastorio, Fabian Zech, Sabrina Noettger, et al.
Cell Host & Microbe (2022) Vol. 30, Iss. 9, pp. 1255-1268.e5
Open Access | Times Cited: 74
The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication
Qin Ning, Di Wu, Xiaojing Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 69

Scroll to top